350 rub
Journal №8 for 2014 г.
Article in number:
Clinical significance of vegf and upa evaluation in breast cancer
Keywords: VEGF uPA breast cancer
Authors:
O.I. Kostyleva - Ph.D. (Med.), Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
L.K. Ovchinnikova - Ph.D. (Med.), Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
V.D. Ermilova - Ph.D. (Med.), Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
U.R. Mamedov - Ph.D. (Med.), Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
I.V. Tereshkina - Ph.D. (Med.), Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
M.V. Gritskevich - Post-graduate Student, Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
O.V. Kuznetsova - Ph.D. (Med.), Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
I.K. Vorotnikov - Dr.Sc. (Med.), Professor, Russian Cancer Research Center of N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russia
Abstract:
The tumor neoangogenesis is an attractive topic of oncology because it is known that tumor growth and development is associated with concomitant forming of mycrovessels, providing cellular breathing and feeding. Vasculoendothelial growth factor (VEGF) is one of the important neoangiogenesis activator, stimulating endotheliocytes proliferation and migration. Urokinase type plasminogen activator (uPA) is playing a key role in process of tumor invasion, contributing to the extracellular mathrix degradation and to more easy endotheliocytes migration. The aim of study - evaluation of serum VEGF levels and tumor cytosols uPA levels in early stages breast cancer patients, and the investigation of their associations with basic clinico-morphological characteristics of breast cancer. In the study 248 breast cancer patients and 55 healthy women were accepted. The blood serum content of VEGF was determined by EIA standarts kits "Quantikine human VAGF" (?R&D Systems Inc.?, USA). The uPA level in cytosol fraction of tumor was evaluated by EIA reactives, created by Dr. T.Benraad (Nymegen, Netherlands). The reliable association between VEGF and uPA levels and stage of disease and or malignancies degree was found by the multivariate analysis. Also association between serum VEGF and tumor cytosols uPA levels in T1 and T2 stages was shown in general group of patients (r=0,67; p=0,001), this correlation was more expressed in lobular infiltrative breast cancer (r=0,92; p=0,001, and significantly less expressed in ductal infiltrative breast cancer (r=0,49; p=0,01). Obtained data support the hypothesis about engagement of VEGF-depending neoangiogenesis and also about its association with urokinase type system plasminogen activation in early stages breast cancer.
Pages: 38-45
References

  1. Kushlinskij N.E., Gershtejn E.S. Biologicheskie markery' opuxolej v klinike - dostizheniya, problemy', perspektivy' // Molekulyarnaya mediczina. 2008. № 3. S. 48 - 55.
  2. Fox S., Generali D., Harris A. Breast tumour angiogenesis // Breast Cancer Res. 2007. V. 9. № 6. P. 216 - 227.
  3. Hatake K., Tokudome N., Ito Y. Next Generation Molecular Targeted Agents for Breast Cancer: Focus on EGFR and VEGFR Pathways // Breast Cancer. 2007. V. 14. № 2. R. 132 - 149.
  4. Gershtejn E.S., Kushlinskij N.E. Faktor rosta e'ndoteliya sosudov kak osnovnoj regulyator angiogeneza i klinicheski znachimy'j pokazatel' pri razlichny'x zlokachestvenny'x novoobrazovaniyax // Texnologii zhivy'x sistem. 2013. T. 10. № 2. S. 18 - 33.
  5. Vandenbunder B., Wernert N., Stehelin D. Does oncogene c-ets 1 participate in the regulation of tumor angiogenesis - // Bull. Cancer. 1993. V. 80. № 1. P. 38 - 49.
  6. Toi M., Hoshina S., Takayanagi T., Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer // Jpn. J. Cancer Res. 1994. V. 85. № 10. P. 1045 - 1049.
  7. Toi M., Inada K., Suzuki H., Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression // Breast Cancer Res. Treat. 1995. V. 36. № 2. P. 193 - 204.
  8. Toi M., Kondo S., Suzuki H. et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer // Cancer. 1996. V. 77. № 6. P. 1101 - 1106.
  9. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer // Cancer Res. 1996. V. 56. № 9. P. 2013 - 2016.
  10. Gershtejn E.S., Shherbakov A.M., Alieva S.K. i dr. Faktor rosta e'ndoteliya sosudov v opuxolyax i sy'vorotke krovi bol'ny'x rakom molochnoj zhelezy' // Byulleten' e'ksperimental'noj biologii i medicziny'. 2003. V. 135. № 1. S. 85 - 88.
  11. Gershtejn E.S., Shherbakov A.M., Alieva S.K. i dr. Faktor rosta e'ndoteliya sosudov v opuxolyax i sy'vorotke krovi bol'ny'x rakom molochnoj zhelezy': svyaz' s kliniko-morfologicheskimi faktorami // Vestnik Rossijskogo onkologicheskogo nauchnogo czentra im. N.N. Bloxina RAMN. 2005. № 1-2. S. 26 - 30.
  12. Kim E.A., Gershtejn E.S., Shherbakov A.M. i dr. Vliyanie neoad''yuvantnoj terapii na urovni VEGF i VEGFR-2 v opuxolyax i sy'vorotke krovi bol'ny'x rakom molochnoj zhelezy' // Voprosy' onkologii. 2008. T. 54. № 3. S. 287 - 293.
  13. Kushlinskij N.E., Gershtejn E.S. Rol' faktora rosta e'ndoteliya sosudov pri rake molochnoj zhelezy' // Byulleten' e'ksperimental'noj biologii i medicziny'. 2002. T. 133. № 6. S. 604 - 612.
  14. Brown L.F., Guidi A.J., Schnitt S.J. et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast // Clin. Cancer Res. 1999. V. 5. № 5. P. 1041-1056.
  15. Shherbakov A.M., Gershtejn E.S., Anurova O.A., Kushlinskij N.E. Faktor rosta e'ndoteliya sosudov i ego reczeptory' pervogo i vtorogo tipa pri rake molochnoj zhelezy' // Voprosy' onkologii. 2005. T. 51. № 3. S. 317 - 321.
  16. Linderholm B.K., Gruvberger-Saal S., Ferno M. et al. Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer // Breast. 2008. V. 17. № 5. P. 484 - 491.
  17. Eppenberger U., Kueng W., Schlaeppi J.M. et al. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients // J. Clin. Oncol. 1998. V. 16. № 9. P. 3129 - 3136.
  18. Coradini D., Boracchi P., Daidone M.G. et al. Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer // Br. J. Cancer. 2001. V. 85. № 6. P. 795 - 797.
  19. Adams J., Carder P.J., Downey S. et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen // Cancer Res. 2000. V. 60. № 11. P. 2898 - 2905.
  20. Gershtejn E.S., Talaeva Sh.Zh., Sandy'baev M.N., Kushlinskij N.E. Klinicheskaya rol' sistemy' aktivaczii plazminogena v opuxolyax cheloveka // Molekulyarnaya mediczina. 2007. № 1. S. 4 - 8.